Skip to main content
UniHealth

Doctor search

George A Fisher, MD

Medical Oncology · Stanford

NPI 1255446308

Medicare standing
Clear
Enrolled, allowed to bill and order, not excluded
Plans that list them
5
2 carriers
Office
1

Offices

1 location · Stanford Health Care · 3,152 clinicians in this group

Looking this up.

Hospitals listed: Stanford Health Care · Stanford Health Care Tri-Valley. That is not proof they admit you there this week.

Plans that list them

5 plans · 2 carriers

A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Fisher’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.

5 of 5 plans

Plans whose provider directory lists this clinician
SCAN Balance (HMO C-SNP)SCAN Health PlanListedOct 3, 2026
SCAN Classic (HMO)SCAN Health PlanListedOct 3, 2026
SCAN MyChoice (HMO)SCAN Health PlanListedOct 3, 2026
SCAN Strive (HMO C-SNP)SCAN Health PlanListedOct 3, 2026
DualConnect (HMO D-SNP)Santa Clara Family Health PlanListedSep 1, 2026

California Medical Board record

Licence G65330 · Current

Licensed to practise in California · since 1989 · expires 2027-03-31 · Stanford University School of Medicine.

No disciplinary actions, convictions, malpractice judgments or citations in this record.

Hospitals they work in

2 hospitals

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

  • Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend it
    Overall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
  • Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend it
    Overall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
See every measure and the patient survey for Stanford Health Care

Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Stanford Health Care
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths5.31 (4.24 to 6.37) · 8,661 casesWorseJul 2022 – Jun 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits14.1 (12.7 to 15.7) · 2,191 casesWorseJan 2024 – Dec 2024
Postoperative respiratory failure rateComplications and deaths4.08 (1.95 to 6.21) · 5,296 casesBetterJul 2022 – Jun 2024
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.317BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.446BetterOct 2024 – Sep 2025
SSI - Colon SurgeryInfections0.241BetterOct 2024 – Sep 2025
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits0.7 (0.6 to 0.9) · 3,348 casesBetterJan 2024 – Dec 2024
Abdominopelvic accidental puncture or laceration rateComplications and deaths1.06 (0.45 to 1.67) · 5,374 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths0.86 (0.72 to 1)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths166.09 (137.88 to 194.3) · 470 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths1.1 · 192 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths6.4 · 146 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths9.7 · 253 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths6.3 · 880 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths10.3 · 935 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths8.7 · 501 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths2.1 · 7,730 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.13 (0 to 0.27) · 20,799 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.28 (0.14 to 0.43) · 23,182 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths0.94 (0.2 to 1.68) · 5,694 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2.36 (1.54 to 3.19) · 7,846 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5.2 (3.76 to 6.64) · 5,603 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.38 (0.23 to 2.53) · 2,211 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.52 (0.21 to 0.83) · 19,915 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths3.6 · 416 casesNoneApr 2023 – Mar 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.869No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections0.857No differentOct 2024 – Sep 2025
SSI - Abdominal HysterectomyInfections0.368No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits16.2 · 247 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits20.5 · 1,021 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits47.8 · 258 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-1.6 · 990 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits20.8 · 976 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits16.5 · 959 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits5.2 (4.4 to 6.2) · 2,191 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits5.1 · 425 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits9.6 · 158 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits19.6 · 183 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits12.7 (10.4 to 15.4) · 4,578 casesNo differentJan 2022 – Dec 2024

What patients said (6,810 patients answered, 25% of those asked)

Patient survey stars by topic at Stanford Health Care
Cleanliness4
Nurse communication4
Doctor communication4
Communication about medicines3
Discharge information4
Overall hospital rating4
Quietness2
Recommend hospital5
Share of patients giving the best answer at Stanford Health Care
Room was "always" clean75%
Nurses "always" communicated well82%
Doctors "always" communicated well81%
Staff "always" explained63%
Yes, staff "did" give patients this information89%
Yes, staff "did" give patients information about help after discharge89%
Doctors "always" explained things so they could understand76%
Doctors "always" listened carefully80%
Doctors "always" treated them with courtesy and respect87%
Patients who gave a rating of "9" or "10" (high)79%
Staff "always" explained new medications76%
Nurses "always" explained things so they could understand77%
Nurses "always" listened carefully79%
Nurses "always" treated them with courtesy and respect88%
"Always" quiet at night53%
"YES", patients would definitely recommend the hospital83%
Staff "always" explained possible side effects50%
Yes, staff "did" give patients information about possible symptoms90%
See every measure and the patient survey for Stanford Health Care Tri-Valley

Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Stanford Health Care Tri-Valley
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.178BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.237BetterOct 2024 – Sep 2025
Abdominopelvic accidental puncture or laceration rateComplications and deaths0.79 (0 to 1.73) · 1,041 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths0.79 (0.5 to 1.08)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths145.81 (96.5 to 195.12) · 72 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths2.9 · 55 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths8.6 · 92 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths12.5 · 96 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths9.5 · 395 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths10.3 · 391 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths10.1 · 162 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths3 · 1,736 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.16 (0 to 0.37) · 4,425 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.22 (0.02 to 0.41) · 4,771 casesNo differentJul 2022 – Jun 2024
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths3.45 (1.46 to 5.44) · 1,403 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths1.5 (0.05 to 2.94) · 645 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths1.81 (0.38 to 3.24) · 1,279 casesNo differentJul 2022 – Jun 2024
Postoperative respiratory failure rateComplications and deaths8.53 (3.2 to 13.85) · 639 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5.15 (1.89 to 8.41) · 648 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.61 (0.14 to 3.07) · 370 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.16 (0 to 0.83) · 4,160 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths4 · 74 casesNoneApr 2023 – Mar 2025
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.369No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections1.112No differentOct 2024 – Sep 2025
SSI - Colon SurgeryInfections0No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits13.1 · 110 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits20.1 · 437 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits-5.8 · 94 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-19.3 · 456 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits-0.3 · 402 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits15.8 · 358 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits6.8 (4.7 to 9.6) · 198 casesNo differentJan 2024 – Dec 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits10.1 (7.5 to 13.6) · 198 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits5.3 · 80 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits10.9 · 46 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits19.3 · 92 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits12.4 (9.6 to 16.2) · 1,532 casesNo differentJan 2022 – Dec 2024
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits1 (0.8 to 1.2) · 929 casesNo differentJan 2024 – Dec 2024

What patients said (1,268 patients answered, 26% of those asked)

Patient survey stars by topic at Stanford Health Care Tri-Valley
Cleanliness3
Nurse communication3
Doctor communication4
Communication about medicines3
Discharge information4
Overall hospital rating3
Quietness2
Recommend hospital4
Share of patients giving the best answer at Stanford Health Care Tri-Valley
Room was "always" clean65%
Nurses "always" communicated well77%
Doctors "always" communicated well79%
Staff "always" explained58%
Yes, staff "did" give patients this information88%
Yes, staff "did" give patients information about help after discharge88%
Doctors "always" explained things so they could understand74%
Doctors "always" listened carefully78%
Doctors "always" treated them with courtesy and respect86%
Patients who gave a rating of "9" or "10" (high)70%
Staff "always" explained new medications72%
Nurses "always" explained things so they could understand73%
Nurses "always" listened carefully74%
Nurses "always" treated them with courtesy and respect84%
"Always" quiet at night42%
"YES", patients would definitely recommend the hospital74%
Staff "always" explained possible side effects44%
Yes, staff "did" give patients information about possible symptoms89%

Original Medicare doctor bills

$71,940

Medicare paid this office $71,940 for 201 people. Most of that is long return visits and Botox.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Largest Original Medicare bills
Long return visit (40+ min)127$46,500$171
Long return visit (40+ min)39$7,324$128
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes17$4,087$105
Return visit (30+ min)30$3,972$120
New patient visit (60+ min)18$3,395$189
See all 6 services
Every Original Medicare service billed
Long return visit (40+ min)127$46,500$171
Long return visit (40+ min)39$7,324$128
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes17$4,087$105
Return visit (30+ min)30$3,972$120
New patient visit (60+ min)18$3,395$189
New patient visit (60+ min)11$1,790$163

Who their Medicare patients are

201 Original Medicare patients in 2024. Average age 75 · Women 42% · Also on Medicaid 16% · Health risk score 2.27. Above the middle of the specialty; the typical medical oncology clinician is at 2.11.

Conditions among them: High blood pressure 69% · Cancer 50% · Diabetes 34% · Coronary heart disease 28% · Chronic kidney disease 26% · Atrial fibrillation 22% · Heart failure 14% · Depression 13% · COPD 9% · Stroke 9% · Dementia 5%.

The office billed $356,038, Medicare allowed $91,330 and paid $71,940; for 474 services of 12 kinds.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Original Medicare by year
2024201474752.27$356,038$71,940
2023237598742.08$435,504$76,244
2022233586742.16$438,685$74,497
2021281862722.19$601,838$107,534
2020250715732.20$367,554$73,412
2019282835722.23$166,636$81,517
2018263697722.32$142,598$68,381
2017254696722.56$181,489$66,887
2016284807722.28$234,179$74,216
2015233664732.21$179,993$59,269
2014287823721.97$223,093$74,821
2013288724732.02$198,941$63,938

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 6 services

Original Medicare services billed in 2023
Long return visit (40+ min)171$51,977$129
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes27$8,551$110
New patient visit (60+ min)45$7,436$165
Initial hospital care with moderate level of medical decision making at least 75 minutes19$3,558$155
Hospital discharge day management, more than 30 minutes12$1,392$107
Return visit (30+ min)13$1,174$90

2022: 4 services

Original Medicare services billed in 2022
Long return visit (40+ min)167$53,786$132
New patient visit (60+ min)50$8,618$172
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes14$4,162$95
Return visit (30+ min)37$3,537$86

2021: 8 services

Original Medicare services billed in 2021
Long return visit (40+ min)170$67,756$136
Return visit (30+ min)92$11,751$90
New patient visit (60+ min)66$11,440$173
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes23$5,632$95
Initial hospital care with moderate level of medical decision making at least 75 minutes23$4,305$179
Hospital discharge day management, more than 30 minutes16$1,601$100
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes15$1,555$65
Short return visit (20+ min)14$960$53

2020: 7 services

Original Medicare services billed in 2020
Long return visit (40+ min)138$39,722$104
New patient visit (60+ min)65$10,200$157
Return visit (30+ min)70$7,145$72
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes24$5,718$95
Initial hospital care with moderate level of medical decision making at least 75 minutes19$3,655$192
Hospital discharge day management, more than 30 minutes17$1,684$99
Short return visit (20+ min)13$1,050$48

2019: 8 services

Original Medicare services billed in 2019
Long return visit (40+ min)141$39,849$100
New patient visit (60+ min)65$9,900$152
Return visit (30+ min)76$8,612$71
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes41$8,301$92
Initial hospital care with moderate level of medical decision making at least 75 minutes32$5,873$184
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes36$5,149$65
Hospital discharge day management, more than 30 minutes19$1,884$99
Hospital discharge day management, 30 minutes or less11$743$68

2018: 7 services

Original Medicare services billed in 2018
Long return visit (40+ min)120$31,138$98
New patient visit (60+ min)77$11,252$146
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes29$7,677$92
Return visit (30+ min)72$7,164$70
Initial hospital care with moderate level of medical decision making at least 75 minutes29$5,640$182
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes19$2,288$65
Hospital discharge day management, 30 minutes or less16$1,070$67

2017: 7 services

Original Medicare services billed in 2017
Long return visit (40+ min)122$33,012$98
Return visit (30+ min)70$7,188$70
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes29$7,104$93
New patient visit (60+ min)45$6,621$147
Initial hospital care with moderate level of medical decision making at least 75 minutes23$4,170$181
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes28$3,628$65
Hospital discharge day management, more than 30 minutes20$1,964$98

2016: 8 services

Original Medicare services billed in 2016
Long return visit (40+ min)145$37,904$95
Return visit (30+ min)86$9,666$65
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes34$7,778$93
New patient visit (60+ min)41$5,911$144
Initial hospital care with moderate level of medical decision making at least 75 minutes29$5,588$180
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes21$1,929$64
Hospital discharge day management, more than 30 minutes11$1,070$97
Hospital discharge day management, 30 minutes or less13$855$66

2015: 7 services

Original Medicare services billed in 2015
Long return visit (40+ min)117$31,166$94
Return visit (30+ min)96$9,647$63
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes21$4,741$93
Initial hospital care with moderate level of medical decision making at least 75 minutes21$4,519$181
New patient visit (60+ min)30$4,498$150
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes15$1,425$65
Short return visit (20+ min)20$909$43

2014: 8 services

Original Medicare services billed in 2014
Long return visit (40+ min)127$35,245$98
Return visit (30+ min)121$13,153$66
New patient visit (60+ min)53$7,765$147
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes38$7,209$92
Initial hospital care with moderate level of medical decision making at least 75 minutes26$4,856$180
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes13$2,050$64
Short return visit (20+ min)35$1,852$43
Hospital discharge day management, more than 30 minutes11$1,062$97

2013: 6 services

Original Medicare services billed in 2013
Long return visit (40+ min)132$26,928$93
Return visit (30+ min)111$12,306$65
New patient visit (60+ min)69$9,916$144
Initial hospital care with moderate level of medical decision making at least 75 minutes32$5,708$173
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes22$4,152$90
Short return visit (20+ min)43$2,163$38

Medicaid work

$5,323 in 2024

Medicaid paid $5,323 for 87 billed services this clinician did in 2024, up to 17 people in a month for one service.

Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.

Largest Medicaid services in 2024
Long return visit (40+ min)50$4,151
SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES37$1,172
Medicaid work by year
202487217$5,323
2023150118$6,534
202255113$3,258
202014113$1,143
See the largest Medicaid services in earlier years

2023

Largest Medicaid services in 2023
Long return visit (40+ min)150$6,534

2022

Largest Medicaid services in 2022
Long return visit (40+ min)55$3,258

2020

Largest Medicaid services in 2020
1ST HOSP IP/OBS HIGH 7514$1,143

Money from drug and device companies

$53 in 2025

Industry payments by year
202511None$53
2024210$3,000$4,763
202334$2,966$4,280
2022612$19,244$19,371
202134$5,781$5,906
2020611$14,519$15,777
2019437$36,894$56,285

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Payments by company
GenentechNone$53
1 payment
  • Education · 2025-10-04 · $53
See the published payment
Every published payment
GenentechEducation · 2025-10-04None$53
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)

2024: $4,763

Payments by company in 2024
ExelixisCabometyx$4,716
9 payments
  • Honoraria for Cabometyx · 2024-05-16 · $3,000
  • Travel for Cabometyx · 2024-04-28 · $77
  • Travel for Cabometyx · 2024-04-26 · $194
  • Travel for Cabometyx · 2024-04-26 · $287
  • Travel for Cabometyx · 2024-04-26 · $769
  • Travel for Cabometyx · 2024-04-26 · $140
  • Meals for Cabometyx · 2024-04-26 · $59
  • Meals for Cabometyx · 2024-04-26 · $105
  • Travel for Cabometyx · 2024-04-25 · $84
E.R. Squibb & Sons L.L.C.None$47
1 payment
  • Meals · 2024-01-17 · $47

2023: $4,280

Payments by company in 2023
AstraZeneca UKImfinzi$2,966
2 payments
  • Consulting for Imfinzi · 2023-10-20 · $2,055
  • Consulting for Imfinzi · 2023-03-17 · $911
E.R. Squibb & Sons L.L.C.None$1,258
1 payment
  • Travel · 2023-01-31 · $1,258
Servier PharmaceuticalsTibsovo$56
1 payment
  • Meals for Tibsovo · 2023-01-23 · $56

2022: $19,371

Payments by company in 2022
AstraZeneca UKImfinzi$5,994
4 payments
  • Consulting for Imfinzi · 2022-08-11 · $1,370
  • Consulting for Imfinzi · 2022-07-21 · $1,028
  • Consulting for Imfinzi · 2022-02-09 · $1,028
  • Consulting for Imfinzi · 2022-02-02 · $2,569
Merck Sharp & DohmeNone$4,270
1 payment
  • Paid to speak or teach · 2022-07-13 · $4,270
E.R. Squibb & Sons L.L.C.None$3,277
4 payments
  • Consulting · 2022-12-30 · $3,150
  • Meals · 2022-10-28 · $47
  • Meals · 2022-10-28 · $27
  • Meals · 2022-10-28 · $54
GenentechNone$2,850
1 payment
  • Consulting · 2022-06-09 · $2,850
F. Hoffmann-La Roche AGTecentriq$1,980
1 payment
  • Consulting for Tecentriq · 2022-04-29 · $1,980
Taiho OncologyLonsurf$1,000
1 payment
  • Consulting for Lonsurf · 2022-01-12 · $1,000

2021: $5,906

Payments by company in 2021
AstraZeneca UKNone$4,281
2 payments
  • Consulting · 2021-09-15 · $3,083
  • Consulting · 2021-09-14 · $1,199
Merck Sharp & DohmeNone$1,500
1 payment
  • Consulting · 2021-07-01 · $1,500
Novartis PharmaceuticalsLutathera$125
1 payment
  • Meals for Lutathera · 2021-12-08 · $125

2020: $15,777

Payments by company in 2020
AstraZeneca ABNone$6,717
1 payment
  • Consulting · 2020-05-08 · $6,717
AstraZeneca UKNone$4,453
2 payments
  • Consulting · 2020-09-29 · $2,398
  • Consulting · 2020-02-28 · $2,055
Merck Sharp & DohmeNone$1,850
2 payments
  • Consulting · 2020-10-21 · $1,250
  • Consulting · 2020-08-17 · $600
Advanced Accelerator ApplicationsLutathera$1,500
1 payment
  • Paid to speak or teach for Lutathera · 2020-05-18 · $1,500
Hoffmann-La RocheNon-Covered Product$1,230
4 payments
  • Travel for Non-Covered Product · 2020-02-26 · $222
  • Meals for Non-Covered Product · 2020-02-26 · $155
  • Travel for Non-Covered Product · 2020-02-26 · $111
  • Travel for Non-Covered Product · 2020-02-26 · $741
Ipsen BiopharmaceuticalsSomatuline Depot$28
1 payment
  • Meals for Somatuline Depot · 2020-01-25 · $28

2019: $56,285

Payments by company in 2019
Merck Sharp & DohmeNone$28,896
26 payments
  • Travel · 2019-07-22 · $150
  • Consulting · 2019-07-22 · $5,500
  • Travel · 2019-07-12 · $211
  • Meals · 2019-07-12 · $42
  • Meals · 2019-07-12 · $60
  • Meals · 2019-07-12 · $62
  • Travel · 2019-07-11 · $252
  • Travel · 2019-07-11 · $554
  • Travel · 2019-04-12 · $38
  • Travel · 2019-04-12 · $60
  • Travel · 2019-03-20 · $200
  • Travel · 2019-03-13 · $150
  • Consulting · 2019-03-13 · $5,500
  • Meals · 2019-03-01 · $125
  • Meals · 2019-03-01 · $35
  • Meals · 2019-03-01 · $50
  • Meals · 2019-03-01 · $50
  • Travel · 2019-02-28 · $614
  • Travel · 2019-02-28 · $265
  • Paid to speak or teach · 2019-02-18 · $10,000
  • Travel · 2019-02-18 · $150
  • Meals · 2019-02-06 · $60
  • Travel · 2019-02-04 · $178
  • Meals · 2019-02-04 · $60
  • Travel · 2019-02-04 · $832
  • Travel · 2019-02-03 · $3,699
Terumo MedicalNone$24,758
5 payments
  • Consulting · 2019-11-07 · $200
  • Consulting · 2019-09-27 · $7,994
  • Travel · 2019-05-20 · $5,351
  • Travel · 2019-05-17 · $5,613
  • Consulting · 2019-03-14 · $5,600
Taiho OncologyTas-102$2,569
5 payments
  • Consulting for Tas-102 · 2019-03-19 · $2,100
  • Meals for Tas-102 · 2019-03-07 · $18
  • Travel for Tas-102 · 2019-03-07 · $67
  • Meals for Tas-102 · 2019-02-28 · $157
  • Travel for Tas-102 · 2019-02-28 · $227
GenentechNon-Covered Product$62
1 payment
  • Meals for Non-Covered Product · 2019-06-02 · $62

Research money

Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.

Research payments by company and study
Genentech, Inc. · Ph Ia Ib Personalized Cancer Vaccine Atezolizumabb · 2022Their institution$299,672
Genentech, Inc. · Ph Ib Personalized Cancer Vaccine Atezolizumabb · 2019Their institution$139,154
Genentech, Inc. · Ph Ia Ib Personalized Cancer Vaccine Atezolizumabb · 2020Their institution$123,587
Genentech, Inc. · Intrinsic Mcrc With Specific Genomic Alterations · 2025Their institution$101,627
Genentech, Inc. · Phib Study of Ro6958688 and Atezolizumab in 3l Mss Mcrc Pts After Pretx With Obinutuzumab · 2020Their institution$89,540
Genentech, Inc. · Ph Ib Personalized Cancer Vaccine Atezolizumabb · 2020Their institution$71,730
Genentech, Inc. · Open Label Dose Escalation Study Safety Pk of Atezolizumab · 2019Their institution$66,011
Genentech, Inc. · Ph Ia Ib Personalized Cancer Vaccine Atezolizumabb · 2024Their institution$59,021
Genentech, Inc. · Cea Tcb Phase 1b Combination With Apd L1 Study · 2019Their institution$45,521
Genentech, Inc. · Cea Tcb Phase 1b Combination With Apd L1 Study · 2021Their institution$37,405
Merck Sharp & Dohme LLC · A Phase III Study of Pembrolizumab Mk-3475 Vs. Chemotherapy in Microsatellite Instability-High Msi-H Or Mismatch Repair Deficient Dmmr Stage IV Colorectal Carcinoma Keynote-177 · 2023Their institution$18,768
Genentech, Inc. · Atezolizumab P1b Combo Atezo and Antivegf Therapies With Solid Tumors · 2021Their institution$17,738
Merck Sharp & Dohme LLC · A Phase II Study of Pembrolizumab Mk-3475 As Monotherapy in Subjects With Previously Treated Locally Advanced Unresectable Or Metastatic Stage IV Mismatched Repair Deficient Or Microsatellite Instability-High Colorectal Carcinoma Keynote-164 · 2022Their institution$11,963
Genentech, Inc. · Eih Pre Lip Mad in Pts · 2020Their institution$9,788
Merck Sharp & Dohme LLC · A Phase III Study of Pembrolizumab Mk-3475 Vs. Chemotherapy in Microsatellite Instability-High Msi-H Or Mismatch Repair Deficient Dmmr Stage IV Colorectal Carcinoma Keynote-177 · 2024Their institution$7,484
Merck Sharp & Dohme LLC · A Phase III Study of Pembrolizumab Mk-3475 Vs. Chemotherapy in Microsatellite Instability-High Msi-H Or Mismatch Repair Deficient Dmmr Stage IV Colorectal Carcinoma Keynote-177 · 2022Their institution$7,315
Genentech, Inc. · Intrinsic Mcrc With Specific Genomic Alterations · 2024Their institution$7,285
Merck Sharp & Dohme Corporation · A Phase II Study of Pembrolizumab Mk-3475 As Monotherapy in Subjects With Previously Treated Locally Advanced Unresectable Or Metastatic Stage IV Mismatched Repair Deficient Or Microsatellite Instability-High Colorectal Carcinoma Keynote-164 · 2019Their institution$5,235
Merck Sharp & Dohme Corporation · A Phase III Study of Pembrolizumab Vs Chemotherapy in Microsatellite Instability- High Or Mismatched Repair Deficient Colorectal Carcinoma · 2021Their institution$3,558
Genentech, Inc. · Eih Pre Lip Mad in Pts · 2021Their institution$3,488
Genentech, Inc. · Ph Ia Ib Personalized Cancer Vaccine Atezolizumabb · 2021Their institution$3,450
Merck Sharp & Dohme Corporation · A Phase II Study of Pembrolizumab Mk-3475 As Monotherapy in Subjects With Previously Treated Locally Advanced Unresectable Or Metastatic Stage IV Mismatched Repair Deficient Or Microsatellite Instability-High Colorectal Carcinoma Keynote-164 · 2021Their institution$1,559
Merck Sharp & Dohme Corporation · A Phase II Study of Pembrolizumab Mk-3475 As Monotherapy in Subjects With Previously Treated Locally Advanced Unresectable Or Metastatic Stage IV Mismatched Repair Deficient Or Microsatellite Instability-High Colorectal Carcinoma Keynote-164 · 2020Their institution$1,459
Genentech, Inc. · Eih Pre Lip Mad in Pts · 2019Their institution$1,280
Genentech, Inc. · Cea Tcb Phase 1b Combination With Apd L1 Study · 2020Their institution$530

Checkups this office reported

Medicare did not publish checkup rates for this clinician.

Medicare’s overall office score
76.5 / 100
Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.

Professional record

NPI
1255446308
Licence
CA G65330California G65330: Current · expires 2027-03-31
Trained
Stanford University School of Medicine, 1987
Video visits
Lists video visits
Gender
Male
More record details
Sole proprietor
No
Medicaid ID
CA 00G653300
Taxonomy
Federal specialty code 207RH0003X (207RH0003X)
Mailing address
2680 Hanover St, Palo Alto, CA, 94304
NPI first listed
2006-08-20
NPI last updated
2009-02-27

This is when the NPI record was last certified, not a medical board exam.